MedTrace Logo

Revacept in Symptomatic Carotid Stenosis

NCT01645306 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.

Patients receive a single dose of trial medication by intravenous infusion for 20 minutes. Patients are followed up one and three days after treatment, at 3 months and by a telephone interview at 12 months.

Conditions

Interventions

DRUG

Revacept

single intravenous injection

DRUG

Placebo

single intravenous injection

Sponsors & Collaborators

  • AdvanceCor GmbH

    lead INDUSTRY

Principal Investigators

  • Holger Poppert, Prof. Dr. · Department of Neurology, TU Munich

  • Ian M Loftus, MD · St George's NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-08
Primary Completion
2018-10-05
Completion
2019-09-23

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01645306 on ClinicalTrials.gov